CoChat
Sign Up
Cited by 93

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

CRISPR/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cells

Kawamura, Norihiko, Nimura, Keisuke, Nagano, Hiromichi, Yamaguchi, Sohei, Nonomura, Norio, Kaneda, Yasufumi·2015·Oncotarget
DOI 10.18632/oncotarget.4293PMC PMC4673169
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.4293

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In vivo CRISPR-mediated knockout of NANOG and NANOGP8 resulted in a decrease of tumorigenic potential in mice.

    “in vivo CRISPR-mediated knockout of NANOG and NANOGP8, genes involved in prostate cancer, resulted in a decrease of tumorigenic potential in mice [160].”

    From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [160]

    The Results section (‘NANOG1 and NANOGP8 knockout decreases the in vivo tumorigenicity of DU145 cells’) reports that knockout cells formed tumors with significantly less potential than parental cells in NOD-SCID mice. However, the paper says the researchers created CRISPR-knockout prostate cancer cell lines and then injected those cells into mice; it does not report performing the knockout in vivo. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 51

  1. Clarke, 2003, Prospective identification of tumorigenic breast cancer cells, Proc Natl Acad Sci, 100, 3983, 10.1073/pnas.0530291100 · DOI
  2. Dirks, 2003, Identification of a Cancer Stem Cell in Human Brain Tumors, Cancer Res, 63, 5821
  3. Tang, 2006, Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells, Oncogene, 25, 1696, 10.1038/sj.onc.1209327 · DOI
  4. Dick, 2007, A human colon cancer cell capable of initiating tumour growth in immunodeficient mice, Nature, 445, 106, 10.1038/nature05372 · DOI
  5. Weissman, 2010, Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271, Nature, 466, 133, 10.1038/nature09161 · DOI
  6. Weinberg, 2008, An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors, Nat Genet, 40, 499, 10.1038/ng.127 · DOI
  7. Chang, 2008, Module Map of Stem Cell Genes Guides Creation of Epithelial Cancer Stem Cells, Cell Stem Cell, 2, 333, 10.1016/j.stem.2008.02.009 · DOI
  8. Dean, 2009, Mouse Fibroblasts Lacking RB1 Function Form Spheres and Undergo Reprogramming to a Cancer Stem Cell Phenotype, Cell Stem Cell, 4, 336, 10.1016/j.stem.2009.02.015 · DOI
  9. Di Fiore, 2010, Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell Content, Cell, 140, 62, 10.1016/j.cell.2009.12.007 · DOI
  10. Tomlinson, 2009, The transcriptional foundation of pluripotency, Development, 136, 2311, 10.1242/dev.024398 · DOI
  11. Smith, 2009, Nanog Is the Gateway to the Pluripotent Ground State, Cell, 138, 722, 10.1016/j.cell.2009.07.039 · DOI · Paper page
  12. Jaenisch, 2005, Ectopic Expression of Oct-4 Blocks Progenitor-Cell Differentiation and Causes Dysplasia in Epithelial Tissues, Cell, 121, 465, 10.1016/j.cell.2005.02.018 · DOI · Paper page
  13. Givol, 2006, Nanog transforms NIH3T3 cells and targets cell-type restricted genes, Biochem Biophys Res Commun, 343, 279, 10.1016/j.bbrc.2006.02.152 · DOI
  14. Corte, 2009, SOX2 Silencing in Glioblastoma Tumor-Initiating Cells Causes Stop of Proliferation and Loss of Tumorigenicity, Stem Cells, 27, 40, 10.1634/stemcells.2008-0493 · DOI
  15. Tang, 2009, Functional Evidence that the Self-Renewal Gene NANOG Regulates Human Tumor Development, Stem Cells, 27, 993, 10.1002/stem.29 · DOI
  16. Screpanti, 2010, Hedgehog controls neural stem cells through p53-independent regulation of Nanog, EMBO, J, 29, 2646, 10.1038/emboj.2010.131 · DOI
  17. Altaba, 2010, NANOG regulates glioma stem cells and is essentialacting in a cross-functional network with GLI1 and p53, EMBO J, 29, 2659, 10.1038/emboj.2010.137 · DOI
  18. Cheung, 2013, Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers, Oncogene, 32, 3500, 10.1038/onc.2012.363 · DOI
  19. Metodiev, 2008, Proteome Profiling of Breast Tumors by Gel Electrophoresis and Nanoscale Electrospray Ionization Mass Spectrometry, J Proteome Res, 7, 1458, 10.1021/pr7007829 · DOI
  20. Okamoto, 2012, Differential expression of nanog1 and nanogp8 in colon cancer cells, Biochem Biophys Res Commun, 418, 199, 10.1016/j.bbrc.2011.10.123 · DOI
  21. Suzuki, 2014, Immunohistochemical expression of four different stem cell markers in prostate cancer: High expression of NANOG in conjunction with hypoxia-inducible factor-1?, expression is involved in prostate epithelial malignancy, Oncol Lett, 8, 985, 10.3892/ol.2014.2274 · DOI
  22. Maitland, 2005, Prospective Identification of Tumorigenic Prostate Cancer Stem Cells, Cancer Res, 65, 10946, 10.1158/0008-5472.CAN-05-2018 · DOI
  23. Wang, 2013, Nanog, a novel prognostic marker for lung cancer, Surg Oncol, 22, 224, 10.1016/j.suronc.2013.08.001 · DOI
  24. Lo, 2008, Positive Correlations of Oct-4 and Nanog in Oral Cancer Stem-Like Cells and High-Grade Oral Squamous Cell Carcinoma, Clin Cancer Res, 14, 4085, 10.1158/1078-0432.CCR-07-4404 · DOI
  25. Smits, 2014, A study of embryonic stem cell-related proteins in human astrocytomas: Identification of Nanog as a predictor of survival, Int J Cancer, 134, 1123, 10.1002/ijc.28441 · DOI
  26. Xu, 2014, The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis, Oncogene, 33, 2655, 10.1038/onc.2013.209 · DOI
  27. Liu, 2011, HIF Induces Human Embryonic Stem Cell Markers in Cancer Cells, Cancer Res, 71, 4640, 10.1158/0008-5472.CAN-10-3320 · DOI
  28. Holland, 2004, Eleven daughters of NANOG, Genomics, 84, 229, 10.1016/j.ygeno.2004.02.014 · DOI
  29. Tang, 2011, NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation, Oncogene, 30, 3833, 10.1038/onc.2011.114 · DOI
  30. Dominko, 2010, Expression of NANOG and NANOGP8 in a variety of undifferentiated and differentiated human cells, Int J Dev Biol, 54, 1743, 10.1387/ijdb.103192sa · DOI
  31. Dai, 2006, NANOGP8 is a retrogene expressed in cancers, FEBS, J, 273, 1723, 10.1111/j.1742-4658.2006.05186.x · DOI
  32. Akashi, 2012, Human Nanog pseudogene8 promotes the proliferation of gastrointestinal cancer cells, Exp Cell Res, 318, 1799, 10.1016/j.yexcr.2012.04.011 · DOI
  33. Dai, 2010, The human pluripotency gene NANOG/NANOGP8 is expressed in gastric cancer and associated with tumor development, Oncol Lett, 1, 457, 10.3892/ol_00000081 · DOI
  34. Serrano, 2014, Reprogramming activity of NANOGP8, a NANOG family member widely expressed in cancer, Oncogene, 33, 2513, 10.1038/onc.2013.196 · DOI
  35. Middendorp, 2012, Nanog and Oct4 overexpression increases motility and transmigration of melanoma cells, J Cancer Res Clin Oncol, 138, 1145, 10.1007/s00432-012-1186-2 · DOI
  36. Persad, 2012, Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail, Br J Dermatol, 166, 1184, 10.1111/j.1365-2133.2012.10824.x · DOI
  37. Longmore, 2011, Temporal and Spatial Cooperation of Snail1 and Twist1 during Epithelial-Mesenchymal Transition Predicts for Human Breast Cancer Recurrence, Mol Cancer Res, 9, 1644, 10.1158/1541-7786.MCR-11-0371 · DOI
  38. Felsenfeld, 2014, A Genome-wide RNAi Screen Identifies Opposing Functions of Snai1 and Snai2 on the Nanog Dependency in Reprogramming, Mol Cell, 56, 140, 10.1016/j.molcel.2014.08.014 · DOI
  39. Wang, 2012, Nanog siRNA plus Cisplatin may enhance the sensitivity of chemotherapy in esophageal cancer, J Cancer Res Clin Oncol, 138, 1759, 10.1007/s00432-012-1253-8 · DOI
  40. Yamanaka, 2003, The Homeoprotein Nanog Is Required for Maintenance of Pluripotency in Mouse Epiblast and ES Cells, Cell, 113, 631, 10.1016/S0092-8674(03)00393-3 · DOI
  41. Melton, 2005, Core Transcriptional Regulatory Circuitry in Human Embryonic Stem Cells, Cell, 122, 947, 10.1016/j.cell.2005.08.020 · DOI · Paper page
  42. Aguilera, 2009, DNA Repair in Mammalian Cells, Cell Mol Life Sci, 66, 1039, 10.1007/s00018-009-8740-3 · DOI · Paper page
  43. Zhang, 2013, Genome engineering using the CRISPR-Cas9 system, Nat Protoc, 8, 2281, 10.1038/nprot.2013.143 · DOI · Paper page
  44. Orkin, 2010, A Myc Network Accounts for Similarities between Embryonic Stem and Cancer Cell Transcription Programs, Cell, 143, 313, 10.1016/j.cell.2010.09.010 · DOI
  45. Sheng Li, 2014, TALEN-mediated Nanog disruption results in less invasiveness, more chemosensitivity and reversal of EMT in Hela cells, Oncotarget, 5, 8393, 10.18632/oncotarget.2298 · DOI
  46. Betsholtz, 2008, Role of platelet-derived growth factors in physiology and medicine, Genes Dev, 22, 1276, 10.1101/gad.1653708 · DOI
  47. Kaneda, 2013, Residual Prostate Cancer Cells after Docetaxel Therapy Increase the Tumorigenic Potential via Constitutive Signaling of CXCR4, ERK1/2 and c-Myc, Mol Cancer Res, 11, 1088, 10.1158/1541-7786.MCR-13-0029-T · DOI
  48. Middendorp, 2012, Nanog and Oct4 overexpression increases motility and transmigration of melanoma cells, J Cancer Res Clin Oncol, 138, 1145, 10.1007/s00432-012-1186-2 · DOI
  49. Kaneda, 2012, TRAIL and Noxa Are Selectively Upregulated in Prostate Cancer Cells Downstream of the RIG-I/MAVS Signaling Pathway by Nonreplicating Sendai Virus Particles, Clin Cancer Res, 18, 6271, 10.1158/1078-0432.CCR-12-1595 · DOI
  50. Masetti, 2012, Epithelial-Stromal Interactions in Human Breast Cancer: Effects on Adhesion, Plasma Membrane Fluidity and Migration Speed and Directness, PLoS ONE, 7, e50804, 10.1371/journal.pone.0050804 · DOI
  51. Eliceiri, 2012, NIH Image to ImageJ: 25 years of image analysis, Nat Methods, 9, 671, 10.1038/nmeth.2089 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Kawamura, N., Nimura, K., Nagano, H., Yamaguchi, S., Nonomura, N., & Kaneda, Y.
Affiliations
  • Division of Gene Therapy Science, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
  • Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2015-06-15
Volume
6
Issue
26
Pages
22361-22374
ISSN
1949-2553
DOI
10.18632/oncotarget.4293
PMC
PMC4673169
Cited by
93
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review